Renalytix AI
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a… Read more
Renalytix AI (RNLX) - Total Assets
Latest total assets as of June 2024: $7.97 Million USD
Based on the latest financial reports, Renalytix AI (RNLX) holds total assets worth $7.97 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Renalytix AI - Total Assets Trend (2018–2024)
This chart illustrates how Renalytix AI’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Renalytix AI - Asset Composition Analysis
Current Asset Composition (June 2024)
Renalytix AI's total assets of $7.97 Million consist of 76.7% current assets and 23.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.7% |
| Accounts Receivable | $722.00K | 9.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Renalytix AI's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Renalytix AI's current assets represent 76.7% of total assets in 2024, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 58.7% of total assets in 2024, down from 73.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 9.1% of total assets.
Renalytix AI Competitors by Total Assets
Key competitors of Renalytix AI based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
UCrest Bhd
KLSE:0005
|
Malaysia | RM48.46 Million |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
China | CN¥265.74 Million |
|
BIT Computer Co. Ltd
KQ:032850
|
Korea | ₩82.38 Billion |
|
ezCaretech Co. LTD
KQ:099750
|
Korea | ₩56.71 Billion |
|
SyntekaBio Inc
KQ:226330
|
Korea | ₩33.49 Billion |
|
Carelabs Co.Ltd
KQ:263700
|
Korea | ₩105.15 Billion |
|
Shanghai Kingstar Winning Software
SHE:300253
|
China | CN¥8.35 Billion |
|
Longmaster Information Tech
SHE:300288
|
China | CN¥1.33 Billion |
Renalytix AI - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Renalytix AI generates 0.29x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Renalytix AI is currently not profitable relative to its asset base.
Renalytix AI - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.53 | 1.67 | 16.42 |
| Quick Ratio | 0.53 | 1.67 | 16.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.38 Million | $ 10.75 Million | $ 20.11 Million |
Renalytix AI - Advanced Valuation Insights
This section examines the relationship between Renalytix AI's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 18.77 |
| Latest Market Cap to Assets Ratio | 2.02 |
| Asset Growth Rate (YoY) | -81.1% |
| Total Assets | $7.97 Million |
| Market Capitalization | $16.11 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Renalytix AI's assets at a significant premium ( 2.02x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Renalytix AI's assets decreased by 81.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Renalytix AI (2018–2024)
The table below shows the annual total assets of Renalytix AI from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | $7.97 Million | -81.07% |
| 2023-06-30 | $42.12 Million | -33.42% |
| 2022-06-30 | $63.26 Million | -38.33% |
| 2021-06-30 | $102.58 Million | +148.38% |
| 2020-06-30 | $41.30 Million | +42.79% |
| 2019-06-30 | $28.92 Million | +50975.48% |
| 2018-06-30 | $56.63K | -- |